CJC-1295 dose range

The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 6 published studies are one click away.

Human trials Growth hormone axis Also called CJC-1295 with DAC

Common use ranges

From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. No drug label. Guides agree on about 100 mcg a shot for the no-DAC form and 1 to 2 mg a week for the DAC form. No study has tested these amounts for regular use.

Half-life: about 6 to 8 days (5.8 to 8.1 days), with DAC
How it is taken: subcutaneous injection
How long people use it: No DAC: 8 to 12 weeks. With DAC: 8 to 16 weeks, then at least 4 weeks off.
Mixing used for the units: 5 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 25 mcg.

Total amount per week, by tier

Tier	Each dose	Syringe units5 mg vial + 2 mL water	How often	Schedule	Vial lastsat this tier
No DAC, starting [1]	100 mcg	4 units 0.04 mL	once a day	100 mcg once a day, before bed on an empty stomach	6+ weeks
No DAC, typical [2]	100 mcg	4 units 0.04 mL	2x a day	100 mcg 2 to 3 times a day, often in the same shot as ipamorelin	about 4 weeks
With DAC, starting [3]	1 mg	40 units 0.40 mL	once a week	0.5 to 1 mg once a week	about 5 weeks
With DAC, higher [4]	2 mg	80 units 0.80 mL	once a week	2 mg once a week, or split into Monday and Thursday	17 days

Good to know

CJC-1295 is sold in two forms. The no-DAC form (Mod GRF 1-29) lasts minutes and is taken daily. The DAC form lasts about a week and is taken weekly. Check which one your vial is.
The CJC-1295 + Ipamorelin blend almost always uses the no-DAC form.

Sources for these amounts

No DAC, starting: Peptide Protocol Wiki, CJC-1295 no DAC dosing
No DAC, typical: Peptide Protocol Wiki, CJC-1295 no DAC dosing
With DAC, starting: Outliyr, CJC-1295 DAC report
With DAC, higher: Outliyr, CJC-1295 DAC report

How long people use it: Peptide Protocol Wiki, CJC-1295 no DAC dosing · Outliyr, CJC-1295 DAC report

Half-life: Teichman et al 2006, J Clin Endocrinol Metab

This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.

See the science: 6 published studies

Amounts given to people in studies

Lowest30 mcg/kg

Most used60 mcg/kg

Highest90 mcg/kg

How it was given: Under the skin (SC), single injection

All human data is for the DAC form. No study of CJC-1295 without DAC (Mod GRF 1-29) was found.

Every study used for this page

Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.

Study	Who was studied	Amount given, as reported	Route	How often	How long	What the authors reported
PMID 163526832006	Human, healthy adults 21-61 yr (n not in abstract)	Not stated in the abstract	SC	Single dose (study 1). Weekly or biweekly, 2 or 3 doses (study 2)	Studies of 28 and 49 days	Two randomised, placebo-controlled, double-blind trials, DAC form. Dose-dependent GH rise 2- to 10-fold for 6 d or more, IGF-I 1.5- to 3-fold for 9-11 d. Half-life 5.8-8.1 d
PMID 170186542006	Human, healthy men 20-40 yr (n not in abstract)	60 or 90 mcg/kg	"injection" (route not in abstract)	Single injection, sampled 1 week later	One dose, 12-h overnight sampling before and 1 wk after	GH pulsatility preserved, trough GH up 7.5-fold, IGF-I up 45%. No difference between the two doses
PMID 193865272009	Human, healthy young men (n = 11)	Not stated in the abstract	"injection"	Single	Sera before and one week after injection	Serum proteomics, biomarker study. No dose data in abstract
PMID 168229602006	Mouse, GHRH-knockout, 1-week-old (n not in abstract; body weight not stated, neonatal)	2 mcg of CJC-1295 per injection	Not in abstract	Every 24, 48 or 72 h	5 weeks	Daily dosing normalised body weight and length. Every 48 or 72 h was less effective
PMID 158176692005	Rat, normal male Sprague Dawley (n not in abstract)	Not stated in the abstract	SC	Single	Acute, GH AUC over 2 h. Plasma present beyond 72 h	CJC-1295 gave 4-fold higher GH AUC than hGRF(1-29). Identified as long-acting analog
PMID 193327892009	Mouse, Br-M3-KO (n not in abstract)	Not stated in the abstract	Not in abstract	Not in abstract	Not in abstract	CJC-1295 rescued growth deficit in M3 receptor knockout mice. No dose data in abstract

How to read the study numbers

One study, one group. Each figure is what one team chose for its own participants or animals.
Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
Short studies. Many studies ran days or weeks. They do not show what happens over longer use.

Common questions

What amounts of CJC-1295 were used in human studies?

In the studies listed here, people were given from 30 mcg/kg up to 90 mcg/kg. The amount used most often was 60 mcg/kg. These are what study teams chose for their participants under supervision.

Where do these CJC-1295 numbers come from?

From 6 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.

How long does CJC-1295 stay in the body?

Its half-life is about 6 to 8 days (5.8 to 8.1 days), with DAC in people. Half-life is how long it takes for half of a dose to leave the blood. The effect can last longer than that.

Is this a recommendation for how much CJC-1295 to use?

No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.

See all peptides